JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Validation of the HFA-ICOS Score for Carfilzomib-Induced Cardiotoxicity in Multiple Myeloma: A Real-Life Perspective Study

  • 0Division of Internal Medicine, University of Torino, 10126 Turin, Italy.
Cancers +

|

July 29, 2025

|

July 29, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

The Heart Failure Association of the European Society of Cardiology and the International Cardio-Oncology Society (HFA-ICOS) score has limited ability to predict Carfilzomib-induced cardiotoxicity in multiple myeloma patients. Integrating systolic blood pressure and pulse wave velocity improved its predictive accuracy.

Area Of Science

  • Cardio-oncology
  • Hematology
  • Cardiovascular Medicine

Background

  • Carfilzomib is associated with cardiotoxicity, but validated risk prediction models for real-world populations are lacking.
  • Early identification of patients at risk for cardiovascular events is crucial for managing Carfilzomib treatment.

Purpose Of The Study

  • To evaluate the performance of the Heart Failure Association of the European Society of Cardiology and the International Cardio-Oncology Society (HFA-ICOS) risk score for Carfilzomib-induced cardiotoxicity.
  • To assess the score's predictive capability in a real-world multiple myeloma patient cohort.

Main Methods

  • Prospective, real-world study of multiple myeloma patients initiating Carfilzomib.
  • Patients were stratified into risk levels using the HFA-ICOS proforma.
  • Cardiovascular and hypertension-related events were monitored.

Main Results

  • The HFA-ICOS score showed limited discriminatory power for cardiovascular events across risk levels (p > 0.05).
  • Over half of patients (52.7%) experienced adverse events, including cardiovascular events (21.3%) and hypertension (45.6%).
  • Integrating systolic blood pressure and pulse wave velocity significantly improved the score's accuracy (AUC 0.557 to 0.736).

Conclusions

  • The HFA-ICOS score alone demonstrated limited predictive value for Carfilzomib-related cardiotoxicity in this cohort.
  • Combining the HFA-ICOS score with systolic blood pressure and pulse wave velocity enhances its performance.
  • Further research is needed to refine risk prediction models for Carfilzomib-induced cardiotoxicity.

Keywords: